This paper examined the liquisolid compact method as one of the tools for greater dissolution of the practically water-insoluble drug famotidine (FM). Therefore, the model drug, FM, has been formulated as directly compacted tablets and liquisolid compacts and then investigated for in-vitro release properties at diverse dissolution circumstances. According to the method, it is possible to convert the liquid medications of water-insoluble drugs in the non-volatile liquid vehicles into reasonably compressible and flowing powders. The formulated systems have been evaluated in terms of the pre-compression factors like the Fourier-transform infrared spectroscopy (FTIR) analysis, flow features of the liquisolid system, differential scanning calorimetry (DSC), post-compression factors, including the content uniformity, hardness, friability and weight variation, disintegration test, invitro dissolution examinations, effects of the dissolution volume as well as pH on the drug release rate and approximation of the fraction of the molecularly dispersed drug in the liquid medication. Since, the liquisolid compacts revealed notably greater drug release rates in comparison to the direct compress tablets in diverse dissolution volumes and pH, it could be concluded that this would be an encouraging approach to the improvement of dissolving the weak water-soluble drugs and formulation of the immediate release solid dose forms.
INTRODUCTION:Increasing the dissolution rate of the in-soluble and or liquid lipophilic drugs for improving the absorption efficacy and bioavailability is a major objective of the drug professionals 1, 2 . A series of the widely used methods for achieving such an objective include the water-soluble salts as well as the polymorphic forms, forming water-soluble molecular complexes, lyophilization, drug micronization, solid dispersion, coprecipitation as well as micro-encapsulation; out of which, 'liquisolid compacts' has been considered a major assuring one 3-6 .